Trending at Lumira Ventures

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia

Alyssia Watkin Iterion Therapeutics, Portfolio News

Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML). This investigator-initiated trial is being led …

Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3

Altamash Hashmi Fusion Pharmaceuticals, Portfolio News

HAMILTON, ON and BOSTON, July 28, 2021 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications …

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

Altamash Hashmi Portfolio News, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of …

Antios Therapeutics and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

Altamash Hashmi Antios Therapeutics, Portfolio News

Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor …